A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Hypercholesterolemia, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 3rd largest by planned enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2001, is one of 33 in phase 3, and was the 24th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,625 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 203 across the 57 interventional studies. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
60 studies in Hypercholesterolemia by AstraZeneca: 3 open now, 3 under way, 3 of them phase 3. Of 55 finished, 7 (13%) have results posted.
Among the 60 studies in Hypercholesterolemia by AstraZeneca, this one is the 2nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2001, is one of 25 in phase 3, and was the 28th registered.
AstraZeneca’s Hypercholesterolemia studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 60 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of various doses of rosuvastatin with atorvastatin, pravastatin \& simvastatin in reducing levels of low density lipoprotein cholesterol in subjects with hypercholesterolaemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rosuvastatin
Drug: Rosuvastatin
Atorvastatin
Drug: Atorvastatin
Pravastatin
Drug: Pravastatin
Simvastatin
Drug: Simvastatin
Also known as: Crestor
Also known as: Lipitor
Also known as: Lipostat
Also known as: Zocor
Percentage change in low density lipoprotein cholesterol.
Time frame: 4 & 6 weeks
Percentage change in other lipid parameters as defined by the protocol
Time frame: 6 weeks
Safety evaluation
Time frame: 6 weeks
No study locations are listed for this record.
The record gives a start of Apr 2001 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin